MedTrace Logo

A Study Comparing the Iron Substitution With the Medicinal Products Ferinject or Monofer

NCT02905539 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2020-11-30

No results posted yet for this study

Summary

The purpose of this study is to determine to what extend a treatment with the iron compounds Iron Isomaltoside 1000 or Ferric Carboxymaltose is leading to hypophosphatemia and to study the potential clinical impact of hypophosphatemia.

Conditions

  • Anemia, Iron-Deficiency

Interventions

DRUG

Iron Isomaltoside 1000

DRUG

Ferric Carboxymaltose

Sponsors & Collaborators

  • Universität des Saarlandes

    lead OTHER

Principal Investigators

  • Gunnar Heine, MD · Universität des Saarlandes

  • Danilo Fliser, MD · Universität des Saarlandes

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2020-06-30
Completion
2020-06-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02905539 on ClinicalTrials.gov